Is Avacta the best ex-penny stock to buy today?

The Avacta share price is up 250% in five years, but can this ex-penny stock maintain this momentum, or is it a bubble waiting to burst?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Burst your bubble thumbtack and balloon background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When successful, penny stocks can be game changers. Tiny companies can explode into industry leaders, sending their stock prices through the roof and make their shareholders very rich. Sadly, such explosive potential also comes with potentially devastating risks.

So far, Avacta (LSE:AVCT) shareholders have enjoyed and endured both sides. Those who invested in this biotech business in 2019 are probably celebrating, given the 250% return. Yet those who hopped on the train in mid-2021 are likely questioning everything, given shares are down almost 75%.

It’s a similar story for those who became shareholders at the start of 2024 since shares have tumbled almost 40%. So what’s going on? And is now the time to start buying?

Volatility of biotech

As a quick reminder, Avacta’s an upcoming diagnostics and cancer therapy specialist. It gained a lot of attention during the pandemic thanks to its lateral flow test kits for Covid-19. But, since the demand for this product has waned significantly following the rollout of vaccines, sales growth has slowed and profitability’s evaporated.

Consequently, investor patience is seemingly running thin. Even more so given the troubles management encountered in receiving regulatory approval for other testing kits in 2023.

This pattern isn’t uncommon for young biotech businesses. Valuations are often driven by expectations. And failing to meet targets can be devastating, especially for small-cap and penny stocks. But is there hope?

Focusing on the long run

As previously mentioned, diagnostics is only one half of this enterprise. The other is cancer therapy. And on that front Avacta’s making encouraging progress.

Following a recent update, Phase 1 clinical trials for its AVA6000 drug have sucessfully completed the second cohort, with the third now underway. That puts the company on track to hit its clinical trial objectives for 2024. And given Phase 1’s where most treatments fail, these positive results are a very encouraging sign.

To help speed things along, the company’s appointed a new scientific advisory board of cancer experts across the US and UK. And with around £35m of cash on the balance sheet, Avacta should have enough capital to complete Phase 1 trials.

Yet, as exciting as this news is, there remains a long journey ahead. There are still two more clinical trial phases to go before reaching the market, each significantly more expensive than the last. And £35m isn’t going to cut it. As such, I wouldn’t be surprised to see large volumes of shareholder dilution moving forward.

But even if it can raise all the necessary funds, that doesn’t guarantee future trials will be a success. Don’t forget over 90% of clinical trials fail.

A risky buying opportunity?

It goes without saying that Avacta’s an incredibly risky investment. Even though its market-cap currently sits outside of penny stock territory at £260m, it seems to be held up almost entirely by expectations of clinical success. After all, shares are currently trading near a price-to-sales ratio of 10.

In other words, even with shares taking a big tumble, they’re still quite expensive. However, should AVA6000 be a success, today’s price may be worth paying. Nevertheless, given that it’s going to be years before AVA6000 will be contributing to sales, assuming it’s successful, this stock seems to me like a massive gamble compared to other opportunities right now. I’m not buying.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »